Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Lithium carbonate

Related Products

Hot Products

Name

Lithium carbonate

EINECS 209-062-5
CAS No. 554-13-2 Density 2.11 g/cm3
PSA 63.19000 LogP -2.44700
Solubility water: 13 g/L (20 °C) Melting Point 720 °C
Formula Li2CO3 Boiling Point 333.6 °C at 760 mmHg
Molecular Weight 73.8912 Flash Point 169.8 °C
Transport Information UN 3264 8/PG 3 Appearance white fine crystalline powder
Safety 8-43-45-37/39-26-36/37-24/25-36/37/39-16-7/8-3/7/9 Risk Codes 36/38-41-36/37/38-22-36-34-20/21/22-15-14-11
Molecular Structure Molecular Structure of 554-13-2 (Lithium carbonate) Hazard Symbols HarmfulXn,CorrosiveC,FlammableF
Synonyms

Lithane;Lithium carbonate;Lithiumcarbonate;Plenur;Liticar;Litard;Limas;Eutimin;Lithea;Priadel;Li2CO3;Phasal;

Article Data 117

Lithium carbonate Synthetic route

124-38-9

carbon dioxide

554-13-2

lithium carbonate

Conditions
ConditionsYield
With C14H14B2(2-)*2Li(1+) In tetrahydrofuran at 25℃; under 760.051 Torr; Sealed tube; Cooling with liquid nitrogen; Inert atmosphere;83%
With Tri-n-octylamine; water; lithium chloride In butan-1-ol under 7.50075E-06 Torr;
With lithium hydroxide monohydrate In water for 2.68333h; Kinetics; Time;
With C2H3OS2(1-)*Li(1+) In methanol

2Li(1+)*W(CO)5(2-)=Li2{W(CO)5}

124-38-9

carbon dioxide

A

14040-11-0

tungsten hexacarbonyl

B

554-13-2

lithium carbonate

Conditions
ConditionsYield
In tetrahydrofuran reductive disproportionation; mechanism discussed;; IR;;A 82%
B 74%
In tetrahydrofuran soln. of the W-compound was treated with gasous CO2 at -78°C, warmed to 25°C; solvent removed (vac.), extd. (diethyl ether), ether removed (vac.); IR, MAS;A 82%
B 74%
584-08-7

potassium carbonate

lithium chloride

554-13-2

lithium carbonate

Conditions
ConditionsYield
In not given pptn. from concd. LiCl soln. with excess of K2CO3;;
In not given pptn. from concd. LiCl soln. with excess of K2CO3;;

lithium nitrate

584-08-7

potassium carbonate

554-13-2

lithium carbonate

Conditions
ConditionsYield
In not given pptn. from concd. LiNO3 soln. with excess of K2CO3;;
In not given pptn. from concd. LiNO3 soln. with excess of K2CO3;;

lithium sulfate

584-08-7

potassium carbonate

554-13-2

lithium carbonate

Conditions
ConditionsYield
In not given
In not given pptn. from concd. Li2SO4 soln. with excess of K2CO3;;
In not given
In not given pptn. from concd. Li2SO4 soln. with excess of K2CO3;;
Conditions
ConditionsYield
With poly(methyl methacrylate); oxalic acid; Ni(CH3COO)2*4H2O In methanol byproducts: NiO; poly(methyl methacrylate) added; pptd. by adding of oxalic acid soln.; calcined at 298-400°C for 1-15 h in mixed atm. air/N2, at 400-600°C in air or O2; powder XRD;
In neat (no solvent, solid phase) heated for 1 h at 500°C; XRD;
6018-89-9

nickel(II) acetate tetrahydrate

A

1313-99-1

nickel(II) oxide

B

lithium nickelate(III)

C

554-13-2

lithium carbonate

Conditions
ConditionsYield
In water mixt. stirred, heated at 120 °C to remove water, heated at 250 °C for 24 h or at 370 °C for 24 h; detd. by XRD;
1310-66-3

lithium hydroxide monohydrate

6018-89-9

nickel(II) acetate tetrahydrate

A

1313-99-1

nickel(II) oxide

B

554-13-2

lithium carbonate

Conditions
ConditionsYield
In neat (no solvent) LiOH*H2O and Ni acetate separately dissolved in H2O; mixed; pH adjusted to 8.5-9.5; heated at 110°C until they were dry; calcined at 300-500°C; monitored by X-ray diffraction;
1310-66-3

lithium hydroxide monohydrate

6018-89-9

nickel(II) acetate tetrahydrate

A

Li2Ni8O10

B

554-13-2

lithium carbonate

Conditions
ConditionsYield
In neat (no solvent) LiOH*H2O and Ni acetate separately dissolved in H2O; mixed; pH adjusted to 8.5-9.5; heated at 110°C until they were dry; calcined at 600°C; monitored by X-ray diffraction;

lithium peroxide

124-38-9

carbon dioxide

554-13-2

lithium carbonate

Conditions
ConditionsYield
High Pressure; at 400°C, pressure of CO2: 2100 at for 6 h;

Lithium carbonate Specification

Lithium carbonate, its cas register number is 554-13-2. It also can be called Lithonate; Lithium hydroxide, solution; Eskalith; and Lithobid. Lithium carbonate, the most widely used of the compounds, is employed in the production of lithium metal and ft-its and enamels. Together with lithium fluoride (LiF), it serves as an additive for cryolite in the elec-trolytic pot line production of primary aluminum. It also is used to treat manic states and bipolar disorder, and is used in the manufacture of most LITHIUM-ion battery cathodes, which are made of lithlum cobalt oxide. It is manufactured from spodumene, which is by far the most important lithium-containing ore.

Physical properties about Lithium carbonate are: (1)ACD/LogP: -0.809; (2)ACD/LogD (pH 5.5): -1.98; (3)ACD/LogD (pH 7.4): -3.77; (4)ACD/BCF (pH 5.5): 1.00; (5)ACD/BCF (pH 7.4): 1.00; (6)ACD/KOC (pH 5.5): 1.00; (7)ACD/KOC (pH 7.4): 1.00; (8)#H bond acceptors: 3; (9)#H bond donors: 2; (10)Flash Point: 169.8 °C; (11)Enthalpy of Vaporization: 63.37 kJ/mol; (12)Boiling Point: 333.6 °C at 760 mmHg; (13)Vapour Pressure: 2.58E-05 mmHg at 25°C

You can still convert the following datas into molecular structure:
(1)InChI=1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2;
(2)InChIKey=XGZVUEUWXADBQD-UHFFFAOYSA-L;
(3)SmilesC(=O)([O-])[O-].[Li+].[Li+];

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral 500mg/kg (500mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 436, 1972.
human TDLo oral 4111mg/kg (4111mg/kg) GASTROINTESTINAL: OTHER CHANGES

BEHAVIORAL: TREMOR

BEHAVIORAL: MUSCLE WEAKNESS
New England Journal of Medicine. Vol. 287, Pg. 867, 1972.
man TDLo oral 8mg/kg (8mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
American Journal of Psychiatry. Vol. 141, Pg. 909, 1984.
man TDLo oral 54mg/kg (54mg/kg) BEHAVIORAL: SLEEP

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"
New Zealand Medical Journal. Vol. 97, Pg. 23, 1984.
man TDLo oral 1080mg/kg/13W (1080mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Journal of Clinical Psychiatry. Vol. 47, Pg. 330, 1986.
man TDLo oral 25gm/kg/4Y-I (25000mg/kg) BEHAVIORAL: TREMOR

SENSE ORGANS AND SPECIAL SENSES: MIOSIS (PUPILLARY CONSTRICTION): EYE
Journal of Clinical Psychiatry. Vol. 46, Pg. 292, 1985.
mouse LD50 intraperitoneal 236mg/kg (236mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: EXCITEMENT
Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973.
mouse LD50 intravenous 497mg/kg (497mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973.
mouse LD50 oral 531mg/kg (531mg/kg)   Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970.
mouse LD50 subcutaneous 413mg/kg (413mg/kg)   Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970.
rat LD50 intraperitoneal 156mg/kg (156mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973.
rat LD50 intravenous 241mg/kg (241mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973.
rat LD50 oral 525mg/kg (525mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973.
rat LD50 subcutaneous 434mg/kg (434mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973.
women TDLo oral 120mg/kg/10D- (120mg/kg) BEHAVIORAL: EXCITEMENT Journal of Clinical Psychiatry. Vol. 48, Pg. 81, 1987.
women TDLo oral 612mg/kg/44D- (612mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE"

BEHAVIORAL: SLEEP
American Journal of Psychiatry. Vol. 152, Pg. 956, 1995.
women TDLo oral 8760mg/kg/2Y- (8760mg/kg) ENDOCRINE: EVIDENCE OF THYROID HYPERFUNCTION 

ENDOCRINE: THYROID WEIGHT (GOITER)
American Journal of Medicine. Vol. 99, Pg. 575, 1995.
women TDLo oral 36500mg/kg/10 (36500mg/kg) ENDOCRINE: DIABETES INSIPIDUS (NEPHROGENIC OR CNS)

KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
Annales de Medecine Interne. Vol. 148, Pg. 284, 1997.
women TDLo unreported 556mg/kg/32D (556mg/kg) BEHAVIORAL: TOXIC PSYCHOSIS JAMA, Journal of the American Medical Association. Vol. 213, Pg. 865, 1970.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 554-13-2